11:49 AM EDT, 10/15/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Tuesday that patient enrollment for its pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer is on track for expected completion by mid-2025.

The trial aims to enroll up to 354 patients, randomized 1:1 to receive either the BriaCell regimen or physician's choice, with a subset of 50 patients receiving Bria-IMT monotherapy, the company said.

BriaCell Therapeutics ( BCTX ) shares rose more than 6% in recent trading.

Price: 0.95, Change: +0.06, Percent Change: +6.22